Global Respiratory Partnering Deals Collection, 2014-2020: Trends, Deal Structure, Leading Deals, Most Active Dealmakers

Dublin, March 10, 2020 (GLOBE NEWSWIRE) -- The "Global Respiratory Partnering 2014-2020: Deal trends, players and financials" report has been added to ResearchAndMarkets.com's offering.

Global Respiratory Partnering 2014 to 2020 provides the full collection of Respiratory disease deals signed between the world's pharmaceutical and biotechnology companies since 2014.

Trends in Respiratory dealmaking in the biopharma industry since 2014
Analysis of Respiratory deal structure
Access to headline, upfront, milestone and royalty data
Access to hundreds of Respiratory deal contract documents
Comprehensive access to over 340 Respiratory deal records
The leading Respiratory deals by value since 2014
Most active Respiratory dealmakers since 2014

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Respiratory disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Respiratory deals.

The report presents financial deal terms values for Respiratory deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of Respiratory dealmaking trends.

Chapter 1 provides an introduction to the report.
Chapter 2 provides an overview of the trends in Respiratory dealmaking since 2014 covering trends by year, deal type, stage of development, technology type and therapeutic indication.
Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.
Chapter 4 provides a review of the leading Respiratory deals since 2014. Deals are listed by headline value. The chapter includes the top 25 most active Respiratory dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 5 provides comprehensive access to Respiratory deals since 2014 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive directory of all Respiratory partnering deals by specific Respiratory target announced since 2014. The chapter is organized by specific Respiratory therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all Respiratory partnering deals signed and announced since 2014. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Respiratory partnering and dealmaking since 2014.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Respiratory technologies and products.

Available deals and contracts are listed by:

Headline value
Upfront payment value
Royalty rate value
Stage of development at signing
Deal component type
Technology type
Specific therapy indication

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Analyzing actual contract agreements allows assessment of the following:

What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are the sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?

Companies Mentioned

3M Drug Delivery Systems
4D Molecular Therapeutics
4D Pharma
AAM Healthcare
Abbvie
Acacia Research
Acorda Therapeutics
Actavis (name changed to Allergan)
Actelion
AdAlta
Adherium
ADM Tronics
Aerocrine
Aerogen
Afimmune
AirWare Labs
Airway Management
AIT Therapeutics
Ajad Medical
Akonni Biosystems
Akorn
Alana Healthcare
ALK-Abello
Allakos
Almirall
Alnylam Pharmaceuticals
Alpine Immune Sciences
American College of Chest Physicians
AMO Pharma
AmorChem
Analytics 4 Life
AnGes MG
Angiodynamics
ANI Pharmaceuticals
Anthem Bluecross
Apax Partners
Aptar Pharma
Aptuit
Aradigm
Aralez Pharmaceuticals
Arch Biopartners
Arcturus Therapeutics
Arena Pharmaceuticals
Aridis Pharmaceuticals
Ario Pharma
Aristea Therapeutics
Ark Biosciences
ARUP Laboratories
Aslan Pharma
Asthma UK
AstraZeneca
Athersys
Auven Therapeutics
Avita Medical
Ayasdi
AzarGen Biotechnologies
Battelle
Baxalta
Bayer
Becton Dickinson
Bellerophon Therapeutics
Bellus Health
Bicycle Therapeutics
Bill and Melinda Gates Foundation
Bina Technologies
Bio-Techne
bioCSL
Biogen
Biomedical Advanced Research and Development Authority
BioMed X Innovation Center
BioReliance
BirchBioMed
Blue Shield of California
Boehringer Ingelheim
Boston University School of Medicine
Breathe Active
Breath Therapeutics
Bridge Biotherapeutics
Brigham and Women's Hospital
Bristol-Myers Squibb
British Lung Foundation
California Institute for Biomedical Research
Camino Partnership
Canadian Institutes of Health Research
Caprion Proteomics
CARB-X
Cardiome Pharma
CareFusion
Cedars-Sinai Medical Center
Celdara Medical
Cell Therapy Catapult
Celon Pharma
Chiesi Farmaceutici
Chinese Future Industry Investment Fund
Cigna Healthcare
Cilag AG
Cincinnati Children's Hospital Medical Center
Cipher Pharmaceuticals
Cipla
Circassia
CMC Biologics
Coalition for Epidemic Preparedness Innovations
Coating Place
Collplant
Columbia University Medical Center
Commense
CompleWare
Context Therapeutics
Cook Medical
COPD Foundation
Corsair Pharma
Cortex Pharmaceuticals
Covalon Technologies
CRS Bio
CSL
Cue Health
Cureveda
Curie-Cancer
Cyclopharm
Daewoong Pharmaceutical
Dalton Pharma Services
DefiniGEN
DEKA Research and Development
Department of Defense
Department of Health and Human Services
Discovery Laboratories
Dizal Pharmaceutical
Domainex
Dr. Reddy's Laboratories
Drukier Institute for Children's Health
DS Biopharma
Ducere Pharma
Duke Clinical Research Institute (DCRI)
Duke University
Eastar Industries
ECM Medical
Eiger BioPharmaceuticals
Electromed
Empatica
Erasmus University Medical Center
ETView Medical
European Commission
European Union
Everest Medicines
EvoRX Technologies
Evotec
Exalenz Bioscience
Exco InTouch
Faes Farma
Faron Pharmaceuticals
Fedora Pharmaceuticals
Fibrocor Therapeutics
Flemish agency for Innovation by Science and Technology
Flextronics
Forge Therapeutics
Fred Hutchinson Cancer Research Center
French National Research Agency
FSC Laboratories
Fujifilm Diosynth Biotechnologies
Galapagos
Galecto Biotech
Galvani Bioelectronics
GE Healthcare
Geisinger Health System
GEn1E Lifesciences
Genentech
GeneOne Life Science
Genome Institute of Singapore
Genten Therapeutics
German Government
Gilead Sciences
GlaxoSmithKline
Glenmark Pharmaceuticals
Government of Australia
Guangzhou Institute of Respiratory Disease
Halyard Health
Haplogen
Harvard Apparatus Regenerative Technology
Harvard Stem Cell Institute
Harvest Capital Strategies
Healios K.K.
Healthcare 21
HealthPrize Technologies
HealthTrust Purchasing Group
Hebrew University of Jerusalem
Hemovent
Heptares Therapeutics
Highmark Blue Shield
Horizon 2020
Hovione
Humanetics
iBio
IBM
Icagen
Icahn School of Medicine at Mount Sinai
IDbyDNA
Ideal Life
IDT Biologika
Ikaria
Imbio
IMI
Impact Instrumentation
Imperial College London
Industrial Technology Research Institute
Inhibrx
Innovate UK
Innovative Genomics Initiative (IGI)
Innovative Medicines Initiative (IMI)
Innovus Pharmaceuticals
INO Therapeutics
Inovio Pharmaceuticals
Insmed Inc
InspiRX Pharma
Integrated Diagnostics
Integrated Vent Solutions
Intrexon
Inventiva
Invion
Jackson Laboratory
Janssen Biotech
Janssen Pharmaceuticals
Janssen Research & Development
Janssen Sciences
JHL Biotech
Johns Hopkins University
Johnson & Johnson Innovation
Jubilant DraxImage
Kamada
KineMed
Knopp Biosciences
Kyorin Pharmaceutical
Laboratory Corporation of America
Laurel Venture Capital
Lawson Health Research Institute
Lee's Pharmaceutical
LFB Biotechnologies
LifeArc
Ligand Pharmaceuticals
Locus Biosciences
Luminex
Lung Biotechnology
Lung Transplant Foundation
Lupin Limited
Lupin Pharmaceuticals
Lyomark Pharma
MannKind Biopharmaceuticals
Masimo
Massachusetts General Hospital
Maxor National Pharmacy
Mayo Clinic
McKesson
Medical Developments International
Medical International Research
Medical Research Council
Medical University of South Carolina
Medical University South Carolina
MedImmune
MediPines
Medtronic
Meiji Seika
Meissa Vaccines
Melinta Therapeutics
MeMed
Menarini
Menarini Asia-Pacific
Merck and Co
Mereo BioPharma
Merit Medical Systems
Monaghan Medical
Morphic Therapeutic
Mount Sinai Health System
MSD
Mundipharma
Mylan Laboratories
Mylan Pharmaceuticals
NacuGen Therapeutics
National Health Service
National Heart
Lung and Blood Institute
National Institute of Allergy and Infectious Diseases
National Institute on Drug Abuse (NIDA)
National Institutes of Health
ndd Medical Technologies
Neos Therapeutics
NeuTec Pharma
New Amsterdam Sciences
Ninepoint Medical
Nippon Kayaku
NitricGen
Nitto BioPharma
Nitto Denko
Nonin Medical
Northern Biologics
Novare Pharmaceuticals
Novartis
Novici Biotech
NTC
Numedicus
NuMedii
Nuvo Pharmaceuticals
Olympus Respiratory America
Omdana Therapeutics
One BioMed
Orion
Owlstone Medical
Oxygen Plus
OxySure Systems
Pantherics
Paragonix Technologies
Parion Sciences
PARI Pharma
Patara Pharma
PatientsLikeMe
Peking University
Pernix Therapeutics
Perrigo
Pfizer
Pfizer Consumer Health
Pharmaxis
Pharmbio Korea
PharmEste
Philips
Pieris
Pillar Palatal
Polarean Imaging
Polyphor
Precision Image Analysis
Propeller Health
ProQR Therapeutics
Prosonix
Protectimmun
Pulmagen Therapeutics
Pulmatrix
Pulmonary Fibrosis Foundation (PFF)
Punjab Province
PureTech Health
Qiagen
QOL Devices
Qualcomm
Qualyst Transporter Solutions
Radboud University Nijmegen Medical Centre
ReadSense Genomic Center
Recipharm
Resmed
Respicardia
Respiratory Motion
rEVO Biologics
Revon Systems
Rhizen Pharmaceuticals
Roivant Sciences
Royal Philips Electronics
Samumed
Sanofi
Santhera Pharmaceuticals
Scholar Rock
Sciex
Seelos Therapeutics
Selvita
Sema4
Sensible Medical Innovations
SenzaGen
Seqirus
Serendex Pharmaceuticals
Serum Institute of India
Shire Pharmaceuticals
Siemens Healthineers
SI Pharmaceuticals
SkyePharma
Snoring Center USA
Sorin Group
Sorrento Therapeutics
SRETT
SteadyMed Therapeutics
Strand Life Sciences
Summa Health System
Sunovion Pharmaceuticals
Surgical Specialties
Sutter Health
Synairgen
Synergie Lyon Cancer
Synthetic Genomics
Takeda Pharmaceutical
TARGET PharmaSolutions
TB Alliance
Technology Strategy Board (UK)
Teijin
Teleflex
Teva Pharmaceutical Industries
TFS International
The Alfred Hospital
The Alpha-1 Project
Theravance
Thermo Fisher Scientific
Third Pole Therapeutics
TiGenix
toSense
Traffick Therapeutics
Tribute Pharmaceuticals
Tris Pharma
TSI Healthcare
UCB
United Therapeutics
University of British Columbia
University of California
San Diego
University of California San Francisco
University of Cambridge
University of Cincinnati
University of Colorado Denver
University of Dundee
University of Manchester
University of Maryland Baltimore
University of Michigan
University of North Carolina
University of Oxford
University of Pittsburgh
University of Rochester Medical Center
US Army
Vasomune Therapeutics
Vectura
VenatoRx
Veracyte
Verily
Vida Diagnostics
Videregen
Vital Connect
Vyaire Medical
Wal-Mart
Walter Reed Army Institute of Research
Watson Laboratories
Weill Cornell Medical College
Wellcome Trust Sanger Institute
Wellmed
Windtree Therapeutics
Wuxi STA
X-Rx
Xenios
XL-Protein
XOR-Labs Toronto
Xvivo Perfusion
Yale School of Medicine
Yale University
Yissum Research Development
YPrime
Yung Shin Pharm
ZAI Laboratory
ZappRx
Zelegent

For more information about this report visit https://www.researchandmarkets.com/r/5siv12

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.


CONTACT: ResearchAndMarkets.com
         Laura Wood, Senior Press Manager
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900

Market News and Data brought to you by Benzinga APIs